

Organized by



Supported By



An Initiative By



01 - 03 MARCH, 2024

BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

REVIEW

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM



01 March, 2024 (Friday)



14:00 - 16:40 Hrs Bali, Indonesia Time



Singaraja 1

14:00 - 14:30

Screening and Surgical Oncology

Speaker: **PETER DUBSKY, SWITZERLAND**

- **GS03-02:** Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
- **GS02-02:** Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
- **GS02-06:** Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection - first results from the international randomized SENOMAC trial
- **GS02-04:** Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival

14:30 - 15:00

Radiation Oncology

Speaker: **FAYE LIM, SINGAPORE**

- **GS02-07:** Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
- **GS02-08:** Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favourable Stage I breast cancer
- **GS03-01:** Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112

15:00 - 15:30

Early-Stage Hormone Receptor Positive Breast Cancer

Speaker: **JAVIER CORTES, SPAIN**

- **GS1-01:** Biomarker results in high-risk estrogen receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer following neoadjuvant chemotherapy ±nivolumab: an exploratory analysis of CheckMate7FL
- **GS01-02:** Phase 3 study of neoadjuvant pembrolizumab or placebo plus

apbcs.org

Organized by



Supported By



An Initiative By



01 - 03 MARCH, 2024

BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

REVIEW

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM



01 March, 2024 (Friday)



14:00 - 16:40 Hrs Bali, Indonesia Time



Singaraja 1

chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756

- **GS03-03:** Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
- **GS03-06:** Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

15:30 - 16:00

Early stage Triple Negative Breast Cancer/HER2 positive Breast Cancer/Survivorship

Speaker: **TIRA TAN, SINGAPORE**

- **GS01-03:** Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
- **GS03-12:** Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
- **GS02-11:** Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
- **GS02-13:** Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

16:00 - 16:20

Advanced Triple Negative and HER2 positive negative Breast Cancer

Speaker: **HOPE RUGO, USA**

- **GS01-05:** Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
- **GS01-10:** HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

apbcs.org

Organized by



Supported By



An Initiative By



01 - 03 MARCH, 2024

BALI NUSA DUA CONVENTION CENTER, BALI, INDONESIA

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM



01 March, 2024 (Friday)



14:00 - 16:40 Hrs Bali, Indonesia Time



Singaraja 1

16:20 - 16:40

Advanced ER Positive HER2 Negative Breast Cancer

Speaker: LEE SOO CHIN, SINGAPORE

- **GS02-01:** Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
- **GS03-13:** Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis
- **GS01-12:** MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer

apbcs.org